ALLMedicine™ Adrenocortical Carcinoma Center

Mar 22nd, 2023 - While most benign lesions of the adrenal glands represent either an adrenocortical adenoma or a myelolipoma, the advent and frequent use of high-resolution radiological investigations have led to relatively increased incidental discovery of rare a...

Mar 17th, 2023 - Adjuvant and neoadjuvant chemotherapy in the treatment of adrenocortical carcinoma (ACC) is limited by few existing trials, most of which are retrospective. The drug mitotane has been used for the treatment of ACC, although existing guidelines onl...

Mar 17th, 2023 - Surgical diseases of the adrenal gland include pheochromocytoma/paraganglioma, primary hyperaldosteronism, Cushing syndrome, and adrenocortical carcinoma. These conditions may be associated with familial syndromes, and genetic testing is available...

Mar 10th, 2023 - Adrenocortical carcinoma (ACC) is a rare malignancy with an estimated annual incidence of only 0.5 to 2.0 per million population and a high rate of mortality: Stage I, II and III 5 years-survival is respectively 84%, 63% and 24%, while medium surv...

Mar 8th, 2023 - Background: Adrenocortical Carcinoma (ACC) is a rare malignancy of the adrenal cortex. The annual incidence of ACC is thought to be between 0.5-2.0 cases per million. Adjunctive therapy with mitotane may be offered post- surgically to minimise ris...

Jan 7th, 2021 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and r...

Jul 9th, 2016 - : By definition, an adrenal incidentaloma is an asymptomatic adrenal mass detected on imaging not performed for suspected adrenal disease. In most cases, adrenal incidentalomas are nonfunctioning adrenocortical adenomas, but may also represent con...

Jun 17th, 2008 - Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism. The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, si...

Mar 10th, 2023 - Adrenocortical carcinoma (ACC) is a rare malignancy with an estimated annual incidence of only 0.5 to 2.0 per million population and a high rate of mortality: Stage I, II and III 5 years-survival is respectively 84%, 63% and 24%, while medium surv...

Mar 8th, 2023 - Background: Adrenocortical Carcinoma (ACC) is a rare malignancy of the adrenal cortex. The annual incidence of ACC is thought to be between 0.5-2.0 cases per million. Adjunctive therapy with mitotane may be offered post- surgically to minimise ris...

Mar 7th, 2023 - This study is a national, multicenter, interventional, phase II clinical trial on the use of pembrolizumab in advanced adrenocortical carcinoma, with confirmed progression within 6 months, following EDP or EDP-M ( etoposide, doxorubicin, cisplatin...

Feb 23rd, 2023 - CABATEN is a multicohort phase II study of cabozantinib plus atezolizumab in advanced and progressive tumors from endocrine system. Hypothesis: The main hypothesis is that the administration of cabozantinib plus atezolizumab will improve the proba...

Feb 21st, 2023 - EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered in combination with nivolumab to generate preliminary safety and efficac...

Aug 23rd, 2022 - New adrenalectomy guidelines from the American Association of Endocrine Surgeons are aimed at assisting both specialist and general surgeons with perioperative adrenal care, including guidance on management of adrenal incidentalomas. Published onl...

Feb 20th, 2022 - The utilization of mitotane (Lysodren) in the adjuvant setting did not produce significant benefit for patients with adrenocortical carcinoma (ACC) at low or intermediate risk of recurrence, according to findings from the phase 3 ADIUVO trial (NCT...

Oct 6th, 2021 - Treatment with the combination of eganelisib (IPI-549), a selective PI3K-γ inhibitor, and nivolumab (Opdivo) demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma (HNSCC), ...

Oct 6th, 2021 - Nikhil Wagle, MD An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib (Votrient), according to r...

Oct 6th, 2021 - Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses immunotherapy in rare genitourinary (GU) cancers. Clinical trials are generally geared to...